佛仁制药品牌怎么样 申请店铺

我要投票 佛仁制药在医疗器械行业中的票数:544 更新时间:2026-01-03
佛仁制药是哪个国家的品牌?「佛仁制药」是 甘肃佛仁制药科技有限公司 旗下著名品牌。该品牌发源于陇南市,由创始人曹明月在2004-03-29期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力佛仁制药品牌出海!将品牌入驻外推网,定制佛仁制药品牌推广信息,可以显著提高佛仁制药产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

佛仁制药怎么样

甘肃佛仁制药科技有限公司是在收购原甘肃武都制药厂的基础上重新组建的一家股份制企业,主要利用地方特色药材资源,从事中成药产品的生产经营,有40多年的生产历史。2010年1月再次通过了国家GMP认证,是药品生产国家GMP认证企业。具有“国药准字”批准文号的产品46个,其中14个品种是2009年国家新选定的国家基本药物。

公司座落于陇南市武都工业园区,占地面积为43亩,建筑面积为5800平方米,总投资为2745万元,形成固定资产投资1120万元。建有中药材前处理、中药提取、综合制剂和动力维修四个车间,拥有片剂、丸剂、颗粒剂、散剂四条生产线。再建的生产线有胶囊剂、糖浆剂、酊剂、煎膏剂、流浸膏剂,以及中药饮片车间。

安装有35000m3/h风量的空气净化装置,总体净化级别达到了10万级,高出了国家要求。设有新产品开发研究所和产品检验质保中心。公司整体生产设备齐全,检验仪器齐全。年具有生产丸剂1000吨(大蜜丸500吨、水丸320吨、浓缩丸180吨),片剂4亿片、颗粒剂2000万袋、散剂300万袋的生产能力。

企业组织机构健全,人员结构合理。现有职工96人,各类专业技术人员占员工总数的28%。企业通过不断的技术改造,采取新工艺,购置新设备,在努力提高产品质量的同时,以务实诚信为经营理念,企业品牌的建设和产品影响力已初具规模,公司为了更及时快捷的给客户提供服务,特在郑州设立全国营销中心,面向全国进行推广,产品遍及全国各地30多个省市。2013年实现销售收入3000多万元,上缴税金200多万元,预计2014年销售收入可达近5000万元,利税在420万元以上。

甘肃佛仁制药科技有限公司无论是产品的技术优势还是市场优势,都具有广阔的发展前景。我们会把可持续发展战略相关产业链上的工作和包括环境保护在内的各项工作做的更好,为推动地方中药材持续发展,带动药农脱贫致富,解决下岗职工再就业,为人类社会和经济的发展做出应有的贡献。


Gansu Furen pharmaceutical science and Technology Co., Ltd. is a joint-stock enterprise re established on the basis of the acquisition of the former Gansu Wudu pharmaceutical factory. It mainly uses local characteristic medicinal materials resources to engage in the production and operation of Chinese patent medicine products, with a production history of more than 40 years. In January 2010, it passed the national GMP certification again, and is a national GMP certification enterprise for drug production. There are 46 products with the approval number of "Guoyao Zhunzi", 14 of which are national essential drugs newly selected by the state in 2009. The company is located in Wudu Industrial Park, Longnan City, covering an area of 43 mu, a building area of 5800 square meters, with a total investment of 27.45 million yuan, forming a fixed asset investment of 11.2 million yuan. There are four workshops for Chinese medicine pretreatment, Chinese medicine extraction, comprehensive preparation and power maintenance, and four production lines for tablets, pills, granules and powders. The newly built production lines include capsule, syrup, tincture, decocting agent, liquid extract, and herbal pieces workshop. The air purification device with 35000m3 / h air volume is installed, and the overall purification level has reached 100000, which is higher than the national requirements. There are new product development research institute and product inspection and Quality Assurance Center. The company has complete production equipment and inspection instruments. The annual production capacity is 1000 tons of pills (500 tons of honey pills, 320 tons of water pills and 180 tons of concentrated pills), 400 million tablets, 20 million bags of granules and 3 million bags of powder. The organizational structure of the enterprise is sound and the personnel structure is reasonable. At present, there are 96 employees, 28% of which are professional technicians. Through continuous technological transformation, adopting new technology and purchasing new equipment, while striving to improve the quality of products, the company has established a national marketing center in Zhengzhou to provide services to customers in a more timely and efficient manner, with pragmatic and honest business philosophy, and its brand building and product influence has taken shape. Its products are spread all over the country Multiple provinces and cities. In 2013, the company realized sales revenue of more than 30 million yuan and paid taxes of more than 2 million yuan. It is estimated that in 2014, the sales revenue will reach nearly 50 million yuan and the profit and tax will be more than 4.2 million yuan. Gansu Furen pharmaceutical science and Technology Co., Ltd. has broad prospects for development, both in terms of technical advantages and market advantages. We will do a better job in the industry chain related to the sustainable development strategy and in various works including environmental protection, in order to promote the sustainable development of local traditional Chinese medicine, drive pharmaceutical farmers out of poverty and become rich, solve the problem of reemployment of laid-off workers, and make due contributions to the development of human society and economy.

本文链接: https://brand.waitui.com/559930f52.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

创历史新高!2025年中国航天发射次数达92次

记者从国家航天局获悉,2025年,我国在载人航天、深空探测、商业航天等领域完成多项突破,实现多个首次。2025年,中国航天全年发射次数达到92次,创历史新高。 (央视新闻)

刚刚

元旦假期,敦煌莫高窟客流同比上涨约30%

敦煌研究院文化弘扬部部长雷政广:从预约数据来看,今年莫高窟元旦假期的游客,增幅应该在30%左右。冬春旅游季,莫高窟的游客主要是以年轻人为主,另外散客占了90%以上的比例。同时省外游客和入境游客,增幅也比较突出。(新浪财经)

刚刚

元旦后陆续入市的公募资金规模在430亿元以上

2026年市场徐徐展开,截至2025年12月31日,元旦后陆续入市的公募资金规模在430亿元以上。一是拟于元旦后上市的16只ETF,合计资金规模近50亿元;二是于2025年11月后成立的60多只处于建仓初期的主动权益基金,合计规模约为380多亿元。 券商中国记者采访了解到,新年上市ETF的持有人,以个人投资者居多,不少产品的个人投资者持有份额占比在90%以上。从底层资金来源看,根据机构预测,居民储蓄资金入市潜力巨大。2026年非定存投资领域有望额外新增2万亿元—4万亿元左右的活化资金。 受访人士对券商中国记者表示,2026年股票投资有望继续领跑,期待居民储蓄能更显著进入股票市场。2026年科技投资难度将大于2025年,超额收益将更依赖于对产业节奏的精准把握和个股的深度甄别,挑战增加,但结构性机遇依然丰富。(e公司)

刚刚

Netflix收购华纳后拟将上映期缩至17天

1月2日,有消息称流媒体巨头Netflix希望在完成对华纳兄弟的收购后,将华纳兄弟电影的院线独占放映期缩短至17天,这一做法引发传统影院及好莱坞电影创作者的担忧。媒体称,在讨论《怪奇物语》第五季大结局院线放映表现时,好莱坞业内对Netflix所称的“行业标准放映窗口”表达了疑虑。消息人士称,Netflix一直主张17天的院线窗口期,而包括AMC在内的院线方则坚持认为应维持在目前常见的45天左右。尽管Netflix尚未最终确定此政策,且未来可能与影院院线协商出一个介于17至45天之间的折中方案,但业内普遍预期,围绕窗口期的谈判将充满张力,而Netflix的核心重点无疑是巩固其流媒体业务。(格隆汇)

刚刚

25年飞天茅台散瓶批价跌至1495元/瓶

“今日酒价”披露的最新批发参考价显示,1月3日,25年飞天茅台原箱报1505元/瓶,较上一日降20元;25年飞天茅台散瓶报1495元/瓶,较上一日降15元。(格隆汇)

刚刚

本页详细列出关于佛仁制药的品牌信息,含品牌所属公司介绍,佛仁制药所处行业的品牌地位及优势。
咨询